~~<i id='1214317F75'><strike id='1214317F75'><tt id='1214317F75'><pre id='1214317F75'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：knowledge 2025-10-04 05:24:00 Page View：9481

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why health records don't always know when patients are dead
Next article： Psychedelics group wrestles with new pharma identity

knowledge

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

SamuelCorum/GettyImagesTheDepartmentofJusticehasaskedafederaljudgetodismissalawsuitbroughtbyHumana,w

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Paxlovid study fails to answer questions over benefit for broader groups

KobiWolf/BloombergPfizersaidTuesdaythatamuch-watchedstudyofitsantiviralPaxlovidinpatientswhohaveCovi